Search Results - Kazuto Tajiri
- Showing 1 - 20 results of 29
- Go to Next Page
-
1
-
2
Liver physiology and liver diseases in the elderly by Kazuto Tajiri
Published 2013Revisão -
3
-
4
Recent advances in the management of pruritus in chronic liver diseases by Kazuto Tajiri, Yukihiro Shimizu
Published 2017Revisão -
5
Branched-chain amino acids in liver diseases by Kazuto Tajiri, Yukihiro Shimizu
Published 2018Revisão -
6
Unsolved problems and future perspectives of hepatitis B virus vaccination by Kazuto Tajiri, Yukihiro Shimizu
Published 2015Revisão -
7
A rapid and efficient single-cell manipulation method for screening antigen-specific antibody–secreting cells from human peripheral blood by Aishun Jin, Tatsuhiko Ozawa, Kazuto Tajiri, Tsutomu Obata, Sachiko Kondo, Koshi Kinoshita, Shinichi Kadowaki, Kazuo Takahashi, Toshiro Sugiyama, Hiroyuki Kishi, Atsushi Muraguchi
Published 2009Artigo -
8
Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pu... by Atsushi Hiraoka, Takashi Kumada, Masatoshi Kudo, Masashi Hirooka, Kunihiko Tsuji, Ei Itobayashi, Kazuya Kariyama, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Toshifumi Tada, Hidenori Toyoda, Kazuhiro Nouso, Kouji Joko, Hideki Kawasaki, Yoichi Hiasa, Kojiro Michitaka
Published 2017Artigo -
9
Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis by Atsushi Hiraoka, Takashi Kumada, Kunihiko Tsuji, Koichi Takaguchi, Ei Itobayashi, Kazuya Kariyama, Hironori Ochi, Kazuto Tajiri, Masashi Hirooka, Noritomo Shimada, Toru Ishikawa, Yoshihiko Tachi, Toshifumi Tada, Hidenori Toyoda, Kazuhiro Nouso, Kouji Joko, Yoichi Hiasa, Kojiro Michitaka, Masatoshi Kudo
Published 2018Artigo -
10
Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis by Atsushi Hiraoka, Takashi Kumada, Kazuya Kariyama, Koichi Takaguchi, Ei Itobayashi, Noritomo Shimada, Kazuto Tajiri, Kunihiko Tsuji, Toru Ishikawa, Hironori Ochi, Masashi Hirooka, Akemi Tsutsui, Hiroshi Shibata, Toshifumi Tada, Hidenori Toyoda, Kazuhiro Nouso, Kouji Joko, Yoichi Hiasa, Kojiro Michitaka
Published 2018Artigo -
11
Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis by Atsushi Hiraoka, Takashi Kumada, Kazuya Kariyama, Koichi Takaguchi, Masanori Atsukawa, Ei Itobayashi, Kunihiko Tsuji, Kazuto Tajiri, Masashi Hirooka, Noritomo Shimada, Hiroshi Shibata, Toru Ishikawa, Hironori Ochi, Toshifumi Tada, Hidenori Toyoda, Kazuhiro Nouso, Akemi Tsutsui, Norio Itokawa, Michitaka Imai, Kouji Joko, Yoichi Hiasa, Kojiro Michitaka
Published 2018Artigo -
12
Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis by Atsushi Hiraoka, Takashi Kumada, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Kazuya Kariyama, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Toshifumi Tada, Hidenori Toyoda, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Korenobu Hayama, Michitaka Imai, Kouji Joko, Yohei Koizumi, Yoichi Hiasa, Kojiro Michitaka, Masatoshi Kudo
Published 2019Artigo -
13
Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib by Atsushi Hiraoka, Takashi Kumada, Shinya Fukunishi, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Kazuya Kariyama, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Toshifumi Tada, Hidenori Toyoda, Keisuke Yokohama, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Korenobu Hayama, Taeang Arai, Michitaka Imai, Kouji Joko, Yohei Koizumi, Yoichi Hiasa, Kojiro Michitaka, Masatoshi Kudo
Published 2019Artigo -
14
Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting by Atsushi Hiraoka, Takashi Kumada, Kazuya Kariyama, Toshifumi Tada, Joji Tani, Shinya Fukunishi, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Kazuhito Kawata, Satoshi Yasuda, Hidenori Toyoda, Hideko Ohama, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Korenobu Hayama, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Kouji Joko, Kojiro Michitaka, Yoichi Hiasa, Masatoshi Kudo
Published 2020Artigo -
15
Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study by Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Joji Tani, Kazuya Kariyama, Shinya Fukunishi, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Kazuhito Kawata, Satoshi Yasuda, Hidenori Toyoda, Tomoko Aoki, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Taeang Arai, Tomomi Okubo, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Koji Joko, Yoichi Hiasa, Masatoshi Kudo
Published 2021Artigo -
16
Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience by Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Kouji Joko, Hiroko Iijima, Yoichi Hiasa, Masatoshi Kudo
Published 2021Artigo -
17
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria – Multicenter... by Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Atsushi Naganuma, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Kouji Joko, Hiroko Iijima, Yoichi Hiasa, Masatoshi Kudo
Published 2021Artigo -
18
Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis by Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Kouji Joko, Hiroko Iijima, Yoichi Hiasa
Published 2022Artigo -
19
New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bev... by Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Kazuya Kariyama, Joji Tani, Masashi Hirooka, Koichi Takaguchi, Masanori Atsukawa, Shinya Fukunishi, Ei Itobayashi, Kunihiko Tsuji, Kazuto Tajiri, Hironori Ochi, Toru Ishikawa, Satoshi Yasuda, Chikara Ogawa, Hidenori Toyoda, Takeshi Hatanaka, Takashi Nishimura, Satoru Kakizaki, Kazuhito Kawata, Noritomo Shimada, Fujimasa Tada, Kazuhiro Nouso, Akemi Tsutsui, Hideko Ohama, Asahiro Morishita, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Hisashi Kosaka, Michitaka Imai, Atsushi Naganuma, Shinichiro Nakamura, Yohei Koizumi, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa
Published 2022Artigo -
20
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clin... by Takaaki Tanaka, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Kouji Joko, Hiroko Iijima, Masaki Kaibori, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada
Published 2022Artigo
Search Tools:
Related Subjects
Medicine
Internal medicine
Hepatocellular carcinoma
Gastroenterology
Oncology
Cancer
Lenvatinib
Sorafenib
Atezolizumab
Bevacizumab
Chemotherapy
Immunotherapy
Nivolumab
Confidence interval
Hazard ratio
Biology
Liver function
Adverse effect
Disease
Immunology
Multivariate analysis
Proportional hazards model
Carcinoma
Etiology
Liver disease
Pembrolizumab
Progressive disease
Amino acid
Bilirubin
Biochemistry